Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05784441 | A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) | PHASE1 | ACTIVE NOT_RECRUITING | 21 | — | — | Nov 6, 2023 | Jan 3, 2040 | Jun 5, 2026 | 15 | United States, Australia +2 |
The safety and tolerability will be measured by recording the occurence and severity of all adverse events or dose limiting toxicities that occur according to Common Terminology Criteria for Adverse Events (CTCAE) criteria version 5.0
Employ a Bayesian optimal interval (BOIN) design and determine the RP2D with review of the number of dose-limiting toxicities
| Arm | Type | Description |
|---|---|---|
| JNJ-90009530 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| JNJ-90009530 | DRUG | JNJ-90009530, an autologous Chimeric Antigen Receptor (CAR) - T therapy targeting CD20 |
Key Inclusion Criteria * Participant must be greater than or equal to (\>=) 18 years of age, at the time of signing informed consent * All participants must have relapsed or refractory disease for each histologic subtype * Mature aggressive large B cell NHL and Follicular Lymphoma Grade 3b: Part...